These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

283 related items for PubMed ID: 32573479

  • 1. Detection of TMPRSS2-ERG Fusion Transcript in Biopsy Specimen of Prostate Cancer Patients: A Single Centre Experience.
    Trifunovski A, Dimovski A, Dohcev S, Stavridis S, Stankov O, Saidi S, Gjorgjievska M, Popov Z.
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2020 Jun 01; 41(1):5-14. PubMed ID: 32573479
    [Abstract] [Full Text] [Related]

  • 2. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA.
    Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, Williamsen S, Hodge P, Meinke J, Blase A, Penabella Y, Day JR, Varambally R, Han B, Wood D, Wang L, Sanda MG, Rubin MA, Rhodes DR, Hollenbeck B, Sakamoto K, Silberstein JL, Fradet Y, Amberson JB, Meyers S, Palanisamy N, Rittenhouse H, Wei JT, Groskopf J, Chinnaiyan AM.
    Sci Transl Med; 2011 Aug 03; 3(94):94ra72. PubMed ID: 21813756
    [Abstract] [Full Text] [Related]

  • 3. Urine TMPRSS2:ERG fusion transcript integrated with PCA3 score, genotyping, and biological features are correlated to the results of prostatic biopsies in men at risk of prostate cancer.
    Cornu JN, Cancel-Tassin G, Egrot C, Gaffory C, Haab F, Cussenot O.
    Prostate; 2013 Feb 15; 73(3):242-9. PubMed ID: 22821767
    [Abstract] [Full Text] [Related]

  • 4. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer.
    Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, Bueti G, Siddiqui J, Tomlins SA, Wei JT, Chinnaiyan AM, Rubin MA, Sanda MG.
    Urol Oncol; 2013 Jul 15; 31(5):566-71. PubMed ID: 21600800
    [Abstract] [Full Text] [Related]

  • 5. Prognostic Significance of TMPRSS2-ERG Fusion Gene in Prostate Cancer.
    Kulda V, Topolcan O, Kucera R, Kripnerova M, Srbecka K, Hora M, Hes O, Klecka J, Babuska V, Rousarova M, Benson V, Pesta M.
    Anticancer Res; 2016 Sep 15; 36(9):4787-93. PubMed ID: 27630329
    [Abstract] [Full Text] [Related]

  • 6. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States.
    Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, Shah RB, Gaston S, Tomlins SA, Wei JT, Kearney MC, Johnson LA, Tang JM, Chinnaiyan AM, Rubin MA, Sanda MG.
    Clin Cancer Res; 2009 Jul 15; 15(14):4706-11. PubMed ID: 19584163
    [Abstract] [Full Text] [Related]

  • 7. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples.
    Miyagi Y, Sasaki T, Fujinami K, Sano J, Senga Y, Miura T, Kameda Y, Sakuma Y, Nakamura Y, Harada M, Tsuchiya E.
    Mod Pathol; 2010 Nov 15; 23(11):1492-8. PubMed ID: 20693979
    [Abstract] [Full Text] [Related]

  • 8. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
    Laxman B, Tomlins SA, Mehra R, Morris DS, Wang L, Helgeson BE, Shah RB, Rubin MA, Wei JT, Chinnaiyan AM.
    Neoplasia; 2006 Oct 15; 8(10):885-8. PubMed ID: 17059688
    [Abstract] [Full Text] [Related]

  • 9. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA, Day JR, Lonigro RJ, Hovelson DH, Siddiqui J, Kunju LP, Dunn RL, Meyer S, Hodge P, Groskopf J, Wei JT, Chinnaiyan AM.
    Eur Urol; 2016 Jul 15; 70(1):45-53. PubMed ID: 25985884
    [Abstract] [Full Text] [Related]

  • 10. TMPRSS2:ERG fusion gene occurs less frequently in Chinese patients with prostate cancer.
    Jiang H, Mao X, Huang X, Zhao J, Wang L, Xu J, Zhang H, Lu Y, Yu Y.
    Tumour Biol; 2016 Sep 15; 37(9):12397-12402. PubMed ID: 27320318
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of urinary prostate cancer antigen-3 (PCA3) and TMPRSS2-ERG score changes when starting androgen-deprivation therapy with triptorelin 6-month formulation in patients with locally advanced and metastatic prostate cancer.
    Martínez-Piñeiro L, Schalken JA, Cabri P, Maisonobe P, de la Taille A, Triptocare Study Group.
    BJU Int; 2014 Oct 15; 114(4):608-16. PubMed ID: 24806330
    [Abstract] [Full Text] [Related]

  • 12. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
    Gerashchenko GV, Mevs LV, Chashchina LI, Pikul MV, Gryzodub OP, Stakhovsky EO, Kashuba VI.
    Exp Oncol; 2018 Jun 15; 40(2):101-108. PubMed ID: 29949537
    [Abstract] [Full Text] [Related]

  • 13. Prevalence and clinical application of TMPRSS2-ERG fusion in Asian prostate cancer patients: a large-sample study in Chinese people and a systematic review.
    Kong DP, Chen R, Zhang CL, Zhang W, Xiao GA, Wang FB, Ta N, Gao X, Sun YH.
    Asian J Androl; 2020 Jun 15; 22(2):200-207. PubMed ID: 31210145
    [Abstract] [Full Text] [Related]

  • 14. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome.
    Clark JP, Munson KW, Gu JW, Lamparska-Kupsik K, Chan KG, Yoshida JS, Kawachi MH, Crocitto LE, Wilson TG, Feng Z, Smith SS.
    Clin Chem; 2008 Dec 15; 54(12):2007-17. PubMed ID: 18948370
    [Abstract] [Full Text] [Related]

  • 15. Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy.
    Merdan S, Tomlins SA, Barnett CL, Morgan TM, Montie JE, Wei JT, Denton BT.
    Cancer; 2015 Nov 15; 121(22):4071-9. PubMed ID: 26280815
    [Abstract] [Full Text] [Related]

  • 16. TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
    Danila DC, Anand A, Sung CC, Heller G, Leversha MA, Cao L, Lilja H, Molina A, Sawyers CL, Fleisher M, Scher HI.
    Eur Urol; 2011 Nov 15; 60(5):897-904. PubMed ID: 21802835
    [Abstract] [Full Text] [Related]

  • 17. Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels.
    Font-Tello A, Juanpere N, de Muga S, Lorenzo M, Lorente JA, Fumado L, Serrano L, Serrano S, Lloreta J, Hernández S.
    Prostate; 2015 Aug 01; 75(11):1216-26. PubMed ID: 25939480
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.